SCHEMBL16385295

SCHEMBL16385295

Cc1cccc(-c2ccc(O)c(F)c2)n1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ HSD17B14 Q9BPX1 5/20 0.53
▸ HSD17B1 P14061 4/20 0.49
▸ HSD17B2 P37059 4/20 0.49
▸ CCR1 P32246 1/20 0.48
▸ CCR8 P51685 1/20 0.48
▸ TGFBR1 P36897 1/20 0.48
▸ ESR1 P03372 7/20 0.46
▸ ESR2 Q92731 7/20 0.46
▸ MEN1 O00255 1/20 0.44
▸ POLB P06746 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ CYP2A6 P11509 1/20 0.44
▸ CYP3A4 P08684 1/20 0.43
▸ CYP2D6 P10635 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ FGFR1 P11362 1/20 0.42
▸ FGFR2 P21802 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2615814 0.84 TGFBR1 (0.62) HSD17B14HSD17B1HSD17B2CCR1CCR8
SCHEMBL16384971 0.83 HSD17B1 (0.56) HSD17B14HSD17B1HSD17B2CCR1CCR8
SCHEMBL10268449 0.83 CCR1 (0.52) HSD17B14HSD17B1HSD17B2CCR1CCR8
SCHEMBL2615821 0.80 CCR1 (0.48) HSD17B14CCR1CCR8TGFBR1MEN1
SCHEMBL16385233 0.80 HSD17B1 (0.53) HSD17B14HSD17B1HSD17B2CCR1CCR8
SCHEMBL16385410 0.80 CCR1 (0.48) HSD17B14HSD17B1HSD17B2CCR1CCR8
SCHEMBL17788165 0.80 HSD17B1 (0.52) HSD17B14HSD17B1HSD17B2CCR1CCR8
SCHEMBL16593187 0.80 TGFBR1 (0.45) HSD17B14HSD17B1HSD17B2CCR1CCR8
SCHEMBL2615816 0.79 MEN1 (0.57) HSD17B14HSD17B1HSD17B2CCR1CCR8
SCHEMBL16606146 0.78 TGFBR1 (0.46) CCR1CCR8TGFBR1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3020715-B1 TETRAZOLINONE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL CO (JP) 2021-06-16 — — EP disclosed
US-9888688-B2 Tetrazolinone compounds and applications thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2018-02-13 — — US disclosed
US-9888688-B2 Tetrazolinone compounds and applications thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2018-02-13 — — US disclosed
US-20160150787-A1 TETRAZOLINONE COMPOUNDS AND APPLICATIONS THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-06-02 — — US disclosed
US-20160150787-A1 TETRAZOLINONE COMPOUNDS AND APPLICATIONS THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-06-02 — — US disclosed
WO-2015005499-A1 TETRAZOLINONE COMPOUND AND USE THEREOF 住友化学株式会社 (JP) 2015-01-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160150787-A1 TETRAZOLINONE COMPOUNDS AND APPLICATIONS THEREOF SOD1, UQCRB, MT-CO1 HSD17B14 3208/4885HSD17B1 1419/4885HSD17B2 2000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback